A disruptive medical device to enable proton therapy as non-invasive and automated treatment of heart arrhythmias

Projektinformationen

Cardio-kit

ID Finanzhilfevereinbarung: 878071

DOI

10.3030/878071

Projekt abgeschlossen

EK-Unterschriftsdatum 18 Juli 2019

Startdatum 1 August 2019

Enddatum 30 November 2019

Finanziert unter

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

EBAMED SA
Switzerland

Periodic Reporting for period 1 - Cardio-kit (A disruptive medical device to enable proton therapy as non-invasive and automated treatment of heart arrhythmias)

Berichtszeitraum: 2019-08-01 bis 2019-11-30

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

EBAMed is a Swiss MedTech Start-up founded in Geneva in 2018 with the mission to provide innovative solutions for non-invasive and effective treatment of heart arrhythmia worldwide. With this purpose in mind, the Company started the development of its ground-breaking proprietary hardware/software solution to enable the use of Proton Therapy for accurate, safe and non-invasive efficient treatment of heart arrhythmia. EBAMed is now focused on the optimization of its technology to maximize its performance before clinical testing. Key objectives of the development are to upgrade the software system and hardware design; to set-up an assembly line; and to validate the system safety and effectiveness through a clinical study to be performed in collaboration with hospitals in Europe. This will enable the Company to lay the ground for CE Mark approval and initial commercialization in Europe.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

During the feasibility assessment, EBAMed defined the users’ requirements and outlined the next phase of the development plan, defining all the optimization and scale-up activities. The Company scouted for key stakeholders to support in the clinical validation stages. EBAMed identified the target market segments and opportunities, defined the Total and Serviceable Addressable markets and established the commercialisation strategy. The Phase 1 feasibility assessment showed a compelling opportunity for the project, validating its technical and commercial viability. The EIC Accelerator Phase 2 funding will provide an important source of non-dilutive funding to complete the planned activities.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

Heart arrhythmia resents a significant burden to patients, ranging from the impact of debilitating symptoms on daily life to the increased risk of stroke and/or death. If not treated efficiently, heart arrhythmia can lead to sudden cardiac arrest, which is a public health problem and accounts for 50% of cardiovascular deaths and 20% of all natural deaths in Western societies. This problem is expected to rise further as the population ages, since sudden cardiac arrest mostly strikes individuals older than 60 years. The population aging worldwide will result in increasing numbers of elderly patients, among whom heart diseases are the leading cause of death. Today, almost a billion people are over 65. EBAMed’s activities represent a unique opportunity to efficiently treat arrhythmia and reduce mortality from heart disease in a safe, non-invasive and effective way. Additionally, proton therapy as a treatment option continues to expand as new facilities continue to be built. The number of proton therapy centers in the EU is steadily increasing and will reach 52 facilities across Europe by 2020.

a4-grey.png